Anthracyclines, as first-line chemotherapy drugs for BC, can promote ICD, specifically by activating the NLRP3 inflammasome to induce adaptive immunity (Ghiringhelli et al., 2009). This evidence concerns the gene NLRP3 and breast cancer.